香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 1 有 關 修 訂 後 的《 公 司 章 程 》全 文 將 刊 發 於 香 港 聯 合 交 易 所 有 限 公 司 網 站 ( www.hkexnews.hk )及本公司網站( www.remegen.com )。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 修訂《公司章程》 本公告乃榮昌生物製藥（煙台）股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則第13.51(1)條作出。 茲提述本公司日期為2025年5月22日的公告（「該公告」）及2025年5月29日的公 告，內容有關配售19,000,000股新H股。除文義另有所指外，本公告所用詞彙與該 公告所界定者具有相同涵義。 因本公司根據一般授權於2025 ...

智通财经APP讯，荣昌生物(688331.SH)发布2025年半年度报告，报告期内，公司实现营业收入10.98亿 元，同比增长48.02%。归属于上市公司股东净亏损4.5亿元，同归属于上市公司股东的扣除非经常性损 益净亏损4.46亿元，基本每股亏损0.83元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 於報告期，我們於推進我們的商業化、產品管線及業務運營方面取得重大進展： 商業化 － 本集團截至2025年6月30日止六個月的產品銷售及研發服務收益為人民幣 1,092.0百萬元，較去年同期的人民幣739.7百萬元增長47.6%，主要由本公 司自身免疫類商業化產品泰它西普（RC18，商品名：泰愛®）及抗腫瘤類商 業化產品維迪西妥單抗（RC48，商品名：愛地希®）的強勁銷售增長帶動。 1 產品管線 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 截至2025年6月30日止六個月 中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月的未經審核簡明合併中期業 績，連同2024年同期的比較數字。 業務摘要 泰它西普（RC18，商品名：泰愛®） 維迪西妥單抗（RC48，商品名：愛地希® ...

Core Insights - Rongchang Biopharmaceuticals reported a significant increase in revenue for the first half of 2025, with total revenue reaching 1.098 billion yuan, a year-on-year growth of 48.02% [1] - The company experienced a net loss of 450 million yuan, which is a 42.40% increase in losses compared to the previous year [1] - The gross profit margin improved to 84.06%, up 5.79 percentage points year-on-year, while the net profit margin was -40.95%, an increase of 64.27 percentage points from the previous year [1] Financial Performance - The basic earnings per share for the first half of 2025 was -0.83 yuan, with a weighted average return on equity of -23.66% [1] - The company's price-to-earnings ratio (TTM) is approximately -32.39, with a price-to-book ratio of about 25.11 and a price-to-sales ratio of around 23.26 [1] - In Q2 2025, the gross profit margin was 84.79%, showing a year-on-year increase of 5.90 percentage points and a quarter-on-quarter increase of 1.53 percentage points [1] Expense Management - Total operating expenses for the first half of 2025 were 1.365 billion yuan, a decrease of 10.85 million yuan compared to the previous year, with an expense ratio of 124.30%, down 61.15 percentage points year-on-year [2] - Sales expenses increased by 34.93%, while management expenses decreased by 0.91%, and research and development expenses fell by 19.72% [2] - Financial expenses rose by 41.75% compared to the previous year [2] Shareholder Dynamics - As of the end of the first half of 2025, the total number of shareholders increased to 12,900, a rise of 6,136 shareholders or 90.69% from the previous quarter [2] - The average market value of shares held per shareholder decreased from 3.2864 million yuan at the end of the first quarter to 2.6429 million yuan, a decline of 19.58% [2] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, is located in the Yantai Free Trade Zone, Shandong, China, and was listed on March 31, 2022 [3] - The company focuses on innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), antibody fusion proteins, and monoclonal antibodies [3] - The main revenue sources are from biopharmaceuticals (98.97%), with minor contributions from technical services (0.64%) and other sources (0.39%) [3]

格隆汇8月22日丨荣昌生物(688331.SH)公布半年度报告，报告期内，销售收入及销量同比增长强劲，公 司实现营业收入10.98亿元，较去年同期的7.42亿元增加48.02%，归属于上市公司股东的净亏损4.50亿 元，归属于上市公司股东的扣除非经常性损益的净亏损4.46亿元，亏损金额同比大幅下降。 ...

Group 1 - The top three companies with the highest short positions as of August 15 are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 14.92%, 14.41%, and 13.40% respectively [1][2] - The companies with the largest absolute increase in short positions are Heng Rui Medicine (01276), Yao Cai Securities (01428), and Modern Animal Husbandry (01117), with increases of 2.49%, 1.34%, and 1.31% respectively [1][2] - The companies with the largest absolute decrease in short positions are Ganfeng Lithium (01772), WuXi AppTec (02359), and Fourth Paradigm (06682), with decreases of -2.98%, -2.67%, and -2.28% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Ping An Insurance (02318) at 12.46%, Green Leaf Pharmaceutical (02186) at 12.36%, and Vanke Enterprises (02202) at 12.13% [2] - The companies with the most significant increases in short ratios include Heng Rui Medicine (01276) from 0.51% to 2.99%, Yao Cai Securities (01428) from 3.47% to 4.81%, and Modern Animal Husbandry (01117) from 4.74% to 6.05% [2] - The companies with the most significant decreases in short ratios include Ganfeng Lithium (01772) from 13.32% to 10.34%, WuXi AppTec (02359) from 17.59% to 14.92%, and Fourth Paradigm (06682) from 2.74% to 0.46% [2][3]

Group 1 - The board of directors of Rongchang Biopharmaceuticals held its 28th meeting, with all 9 directors present, confirming compliance with relevant laws and regulations [1][2] - The board approved the unaudited consolidated financial statements for the six months ending June 30, 2025, which were reviewed by the audit committee [1][3] - The board decided not to declare an interim dividend for 2025, considering the company's overall financial condition and capital needs [2][3] Group 2 - The board approved the company's 2025 interim report and its summary, ensuring compliance with regulations and confirming the accuracy and completeness of the information [2][3] - A special report on the use of raised funds for the first half of 2025 was also approved, with details available on the Shanghai Stock Exchange website [3][5] - The board reviewed and confirmed the effectiveness of the company's risk management and internal control systems for the first half of 2025 [4][5] Group 3 - The board confirmed compliance with the Corporate Governance Code and related rules, with no violations reported during the first half of 2025 [4][5] - An evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was approved, summarizing the execution status for the first half of the year [4][5] - The board approved changes to the registered capital and amendments to the company's articles of association following the issuance of 19 million H shares on May 29, 2025 [5][6] Group 4 - The board reviewed the progress of the company's Environmental, Social, and Governance (ESG) goals for 2025, focusing on sustainable development and social responsibility [5][6]

（文章来源：每日经济新闻） 荣昌生物8月22日晚间发布公告称，公司第二届第二十八次董事会会议于2025年8月22日在公司会议室以 现场结合通讯方式召开。会议审议了《关于<2025年度"提质增效重回报"行动方案的半年度评估报告> 的议案》等文件。 ...

Core Insights - Rongchang Bio reported a revenue of approximately 1.098 billion yuan for the first half of 2025, representing a year-on-year increase of 48.02% [2] - The net loss attributable to shareholders was approximately 450 million yuan, with a basic earnings per share loss of 0.83 yuan [2] - In comparison, the revenue for the same period in 2024 was about 742 million yuan, with a net loss of approximately 780 million yuan and a basic earnings per share loss of 1.45 yuan [2] Financial Performance - Revenue for H1 2025: 1.098 billion yuan, up 48.02% year-on-year [2] - Net loss for H1 2025: 450 million yuan [2] - Basic earnings per share for H1 2025: loss of 0.83 yuan [2] - Revenue for H1 2024: 742 million yuan [2] - Net loss for H1 2024: 780 million yuan [2] - Basic earnings per share for H1 2024: loss of 1.45 yuan [2]

荣昌生物制药（烟台）股份有限公司 章 程 荣昌生物制药（烟台）股份有限公司 2025 年 8 月 | 第一章 | 总则 4 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 6 | | | 第三章 | 股份 6 | | | 第一节 | 股份发行 | 6 | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 | 8 | | 第四章 | 股东和股东会 9 | | | 第一节 | 股东的一般规定 | 9 | | 第二节 | 控股股东和实际控制人 | 12 | | 第三节 | 股东会的一般规定 | 13 | | 第四节 | 股东会的召集 | 15 | | 第五节 | 股东会的提案与通知 | 17 | | 第六节 | 股东会的召开 | 18 | | 第七节 | 股东会的表决和决议 | 21 | | 第五章 | 董事和董事会 24 | | | 第一节 | 董事的一般规定 | 24 | | 第二节 | 董事会 | 28 | | 第三节 | 独立董事 | 32 | | 第四节 | 董事会专门委员会 | 36 | | 第六章 | 高级管理人员 38 | | | 第七章 | 财务 ...